Mark Oldakowski Net Worth

Mark Oldakowski biography

Mark Oldakowski serves as Chief Operating Officer of the Company. Mr. Oldakowski has served as our Chief Operating Officer since November 2017 and previously served as our Vice President, Product Development and Operations since October 2014. From December 2011 to August 2014, Mr. Oldakowski served as the Senior Director of Engineering and Chief Product Officer at Brooks Life Science Systems, a provider of automation and cryogenic solutions for the life science industry, and from April 2009 to October 2011 as a Director of Engineering at Affymetrix, Inc., a private life science systems company that was acquired by Thermo Fisher Scientific in March 2016. From December 2007 to April 2009, Mr. Oldakowski served as a Senior Manager and Core Team Leader of R&D for Siemens Healthcare Diagnostics, and for the prior 13 years, he developed sequencing and real-time PCR systems at Applied Biosystems, now a part of Thermo Fisher Scientific. Mr. Oldakowski received both his bachelor’s degree in electrical engineering and his master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute.

What is the salary of Mark Oldakowski?

As the Chief Operating Officer of Bionano Genomics Inc, the total compensation of Mark Oldakowski at Bionano Genomics Inc is $546,854. There are 1 executives at Bionano Genomics Inc getting paid more, with R. Erik Holmlin having the highest compensation of $898,590.

How old is Mark Oldakowski?

Mark Oldakowski is 46, he's been the Chief Operating Officer of Bionano Genomics Inc since 2017. There are 8 older and no younger executives at Bionano Genomics Inc. The oldest executive at Bionano Genomics Inc is David Barker, 78, who is the Independent Chairman of the Board.

What's Mark Oldakowski's mailing address?

Mark's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at Bionano Genomics Inc

Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart e Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.

What does Bionano Genomics Inc do?

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o

Bionano Genomics Inc executives and stock owners

Bionano Genomics Inc executives and other stock owners filed with the SEC include:

• R. Erik Holmlin,
  President, Chief Executive Officer, Director
• Mark Oldakowski,
  Chief Operating Officer
• Dr. Robert Erik Holmlin,
  Pres, CEO, Sec. & Director
• David Barker,
  Independent Chairman of the Board
• Christopher P. Stewart,
  Chief Financial Officer
• Kristiina Vuori,
  Independent Director
• Christopher Twomey,
  Independent Director
• Albert Luderer,
  Independent Director
• Hannah Mamuszka,
  Director
• Yvonne Linney,
  Director
• Alka Chaubey,
  Chief Medical Officer
• Christopher Stewart,
  Chief Financial Officer
• Dr. Charles Lee Ph.D.,
  Scientific Advisor
• Prof. Pui-Yan Kwok,
  Scientific Advisor
• Dr. Paul R. Selvin Ph.D.,
  Scientific Advisor
• Mark Adamchak,
  Controller
• Richard Shippy,
  Chief Bus. Officer
• Robert J. Priar,
  Chief Commercial Officer
• Dr. Alka Chaubey FACMG, Ph.D.,
  Chief Medical Officer
• Aleksandar Rajkovic,
  Director
• Robert J Priar,
  Chief Commercial Officer
• Michael James Ward,
  Former Chief Financial Officer
• Heather Adams,
  Chief Administrative Officer
• Warren Robinson,
  Chief Commercial Officer
• Darren Cai,
  Director
• Quan Zhou,
  Director
• Junfeng Wang,
  Director
• Soheil Shams,
  Chief Informatics Officer
• Richard Shippy,
  Chief Business Officer
• Vincent Jung Fai Wong,
  Director
• Jonathan V. Dixon,
  GENERAL COUNSEL
• Gulsen Kama,
  Chief Financial Officer